Imiquimod as an antiaging agent.

Background: Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatologic diseases. Several published reports have validated the benefit of imiquimod therapy for actinic keratoses and superficial melanoma and nonmelanoma skin cancers. There is, however, limited evidence demonstrating the use of topical imiquimod application as an antiaging treatment.

Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.

Background: Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.

Objective: To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.